Canaccord Initiates Illumina Coverage with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity today started coverage of Illumina with a Buy rating and a $275 price target on the firm's stock. 

Noting the flush next-generation sequencing market and the large shadow cast by Illumina in the space, Canaccord analyst Mark Massaro called Illumina "a must-own stock for large-cap growth … given the company's dominant leadership position, innovation, and pipeline in the dynamic next-generation sequencing market opportunity we peg at close to $50 billion by the end of the decade." 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Mar
16
Sponsored by
Agilent Technologies

This online seminar will discuss how improvements on the front end and back end of the sequencing workflow can lead to better RNA-seq results.

Mar
28

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.